Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GFT505 Reduces the Risk of Cardiovascular Events

Published: Friday, May 17, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
Treatment with GFT505 significantly reduces the level of “remnant cholesterol”.

GENFIT has announced that GFT505 reduces a new component of cardiovascular risk: the cholesterol contained in lipid particles other than LDL and HDL, also known as ‘remnant cholesterol’.

All the Phase II clinical studies performed to date have shown that GFT505 improves classical lipid risk factors. It lowers the level of LDL-cholesterol (‘bad cholesterol’), increases the level of HDL-cholesterol (“good cholesterol”), and lowers the level of non-HDL-cholesterol and triglycerides in the blood.

A recently published study (Varbo et al. J Am Coll Cardiol 2013; 61: 427-36) of more than 70,000 subjects shows that the level of cholesterol not contained in LDL or HDL particles, also known as ‘remnant cholesterol’, is directly and causally associated with an elevated risk of ischemic heart disease.

According to this study, subjects with increased levels of remnant cholesterol have a two- to three-fold greater risk of developing ischemic heart disease than subjects with low levels of remnant cholesterol.

The data from the Phase IIa studies, GFT505-209-4 in pre-diabetic patients and GFT505-210-5 in diabetic patients, have been analyzed.

This analysis demonstrates that treatment with GFT505 (80 mg/day) significantly reduces the level of “remnant cholesterol” in these two patient populations.

In the GFT505-209-4 study, the effect of GFT505 on measured remnant cholesterol was -24% (p=0.0046) compared to the placebo group after 28 days of treatment.

Consistently, after 3 months of treatment in diabetic patients (study GFT505-210-5), the effect of GFT505 on calculated remnant cholesterol compared to the placebo group was -46% (p=0.01).

Two experts commented these results.
Professor Gerald Watts (University of Western Australia) declared: “GFT505, when administered as monotherapy to patients with pre-diabetes or diabetes, leads to a significant fall in plasma triglyceride and triglyceride-rich lipoprotein remnants. The 10-15% reduction in non-HDL cholesterol could be clinically significant in terms of a proportional reduction in cardiovascular events in patients with the metabolic syndrome.”

Professor Bart Staels, University of Lille 2 and President of the Scientific Advisory Board, precised: “NAFLD/NASH is considered to be the hepatic complication of the metabolic syndrome. Overall, the results of large outcome trials show that statin treatment decreases the cardiovascular risk by only 30%, the remaining 70% representing a high residual cardiovascular risk. Given Varbo et al’s demonstration of the causal link between the level of remnant cholesterol and cardiovascular risk, the beneficial effects of GFT505 on remnant cholesterol further strengthen its cardioprotective profile.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Grants Fast Track Designation to GENFIT's GFT505 in NASH
The aim is to ensure that new therapies for serious conditions are approved and available to patients as soon as possible.
Tuesday, February 18, 2014
GENFIT: The FDA Grants Fast Track Designation to GFT505 in NASH
Granting accelerate the development of GFT505 and reduce the time to market.
Tuesday, February 18, 2014
Genfit: Milestone Achieved as a Compound Developed in Partnership Enters the Clinic
Genfit has announced that it has achieved a milestone in the therapeutic research collaboration with one of its strategic pharmaceutical partners.
Thursday, May 06, 2010
GENFIT Assembles Four International Experts for it's Scientific Advisory Board
GENFIT, a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, announces a new Scientific Advisory Board consisting of internationally renowned experts.
Thursday, October 30, 2008
Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!